The settlement agreement will extend market exclusivity for AbbVie's JAK inhibitor in the U.S. until 2037—providing pediatric ...

President Donald Trump is considering tariff exemptions for certain “non-patented” pharmaceuticals, though the White House ...

Ocaliva won accelerated approval for primary biliary cholangitis in 2016, which the FDA refused to upgrade to full approval ...

Capsida has yet to disclose the exact cause of death. The patient had received the gene therapy CAP-002 for a type of ...

Analysts at BMO Capital Markets expect the lack of other exon-44-skiping therapies to facilitate a "smooth" approval process ...

New York City has seen increased life sciences employment during the past decade as public funding and key projects like ...

The biopharma job market remains challenging, based on BioSpace data. In August, job postings live on the website dropped 32% ...

Novo Nordisk also lowered its full-year profit growth guidance in connection with the restructuring effort. The pharma now ...

Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

A draft executive order obtained by The New York Times purports to clamp down on the pharmaceutical industry's ability to buy new molecules from biotechs based in China, along with a number of other ...

Former CDC director Susan Monarez and former chief medical officer Debra Houry will appear in front of the Senate HELP ...

Suddenly one obesity asset has come to define Amgen but executives see a fuller portfolio that will bring the big biotech ...